• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:MDXXF)

0.0782 -0.0030 (-3.69%)
Streaming Delayed Price Updated: 12:38 PM EDT, Mar 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,899
Open 0.0782
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0812
Today's Range 0.0782 - 0.0782
52wk Range 0.0614 - 0.1550
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Cortexa Advances Commercialisation of MDMA Supply in Australia
March 23, 2026
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research
January 08, 2026
From PharmAla Biotech
Via GlobeNewswire

Performance

YTD
-10.9%
-10.9%
1 Month
+5.2%
+5.2%
3 Month
-2.2%
-2.2%
6 Month
-3.5%
-3.5%
1 Year
-49.5%
-49.5%

More News

Read More
News headline image
PharmAla Biotech Australia Contracts with UK-based CDMO for Manufacture of ALA-002 Drug Substance
December 15, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
Small Cap Growth Virtual Investor Conference Agenda Announced for October 16th
October 17, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
PharmAla Completes Shipment of LaNeo™ MDMA to Johns Hopkins
October 02, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
Small Cap Growth Virtual Investor Conference Agenda Announced for October 16th
October 14, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
PharmAla Completes Shipment of LaNeo™ MDMA to Yale University, Provides Investor Update
June 03, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Contracts with Partner to Act as US Distributor
March 24, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA
February 27, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli
February 06, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
January 20, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Biotech To Supply LaNeo MDMA For Mt. Sinai Clinical Trial ↗
October 21, 2024
Via Benzinga
News headline image
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
October 21, 2024
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Biotech To Supply University Of Texas, San Antonio For Clinical Trial ↗
October 08, 2024
Via Benzinga
News headline image
PharmAla Biotech To Supply MDMA For Harvard's Maclean Hospital Clinical Trial ↗
October 02, 2024
Via Benzinga
News headline image
PharmAla Biotech Partners With Johns Hopkins University For MDMA Clinical Trials, Terminates Red Light Holland Contract ↗
September 11, 2024
Via Benzinga
News headline image
PharmAla Launches MDMA Clinical Trial Tool for Researchers
August 22, 2024
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
August 09, 2024
From PharmAla Biotech
Via GlobeNewswire
News headline image
Canadian Biotech Duo Hits Psilocybin Extraction Milestone For API Development At Scale ↗
May 29, 2024
Via Benzinga
News headline image
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More ↗
April 17, 2024
Via Benzinga
News headline image
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
April 05, 2024
From PharmAla Biotech
Via GlobeNewswire
News headline image
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More ↗
March 30, 2024
Via Benzinga
News headline image
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗
March 29, 2024
Via Benzinga
News headline image
PharmAla's Novel MDMA Mixture Awarded US Patent, Enabling IP Protection And Further Development ↗
March 27, 2024
Via Benzinga
Topics Intellectual Property
News headline image
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
March 27, 2024
From PharmAla Biotech
Via GlobeNewswire

Frequently Asked Questions

Is MDXXF publicly traded?
Yes, MDXXF is publicly traded.
What exchange does MDXXF trade on?
MDXXF trades on the OTC Traded
What is the ticker symbol for MDXXF?
The ticker symbol for MDXXF is MDXXF on the OTC Traded
What is the current price of MDXXF?
The current price of MDXXF is 0.0782
When was MDXXF last traded?
The last trade of MDXXF was at 03/23/26 12:38 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap